Adhera Therapeutics, Inc. engages in the discovery, development, and commercialization of drug therapeutics for hypertension. It offers Perstalia, which contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension. The company was founded on September 23, 1983 and is headquartered in Durham, NC.
Company profile
Website
CEO
Nancy R. Phelan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
841043826
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Nov 04
POS AM
Prospectus update (post-effective amendment)
22 Nov 04
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Nov 04
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Nov 04
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Nov 04
425
Business combination disclosure
10 Nov 04
10-Q
2004 Q3
Quarterly report
9 Nov 04
8-K
Atrix Laboratories Reports 2004 Third Quarter Financial Results
9 Nov 04
425
Business combination disclosure
21 Oct 04
425
Business combination disclosure
15 Oct 04
Latest ownership filings